zurück

Lonafarnib (Hutchinson-Gilford progeria syndrome or (processing-deficient) progeroid laminopathy)

 

Subject:

  • Active Substance: Lonafarnib
  • Name: Zokinvy®
  • Therapeutic area: Hutchinson-Gilford progeria syndrome or progeroid laminopathy
  • Pharmaceutical company: EigerBio Europe Ltd.

 

Time table:

  • Start: 15.10.2022
  • Publication of assessment: 16.01.2023
  • End of public hearing: 06.02.2023
  • Final decision by G-BA: beginning of April 2023

 

Comparative therapy:

  • No comparative therapy due to orphan drug designation